sorry if this has already been posted......
Transplantation 1998 Dec 27;66(12):1732-5
Recombinant human tumor necrosis factor receptor Fc fusion protein
therapy in kidney transplant recipients undergoing OKT3 induction
therapy.
Novak EJ, Blosch CM, Perkins JD, Davis CL, Barr D, McVicar JP, Griffin RS, Farrand AL, Wener M, Marsh CL
Department of Surgery, University of Washington, Seattle 98195, USA.
[Medline record in process]
BACKGROUND: Initial doses of OKT3 are associated with a cytokine-induced acute clinical syndrome (ACS). This study
assessed the safety of a recombinant human tumor necrosis factor receptor fusion protein (TNFR:Fc) given to minimize
OKT3-ACS symptoms in renal allograft recipients undergoing induction therapy. METHODS: Sixteen patients were
randomized into treatment or control groups. Treated patients received TNFR:Fc 1 hr before OKT3 on days 0 and 3. Patients
were monitored after transplant for OKT3-ACS symptoms. Levels of cytokines, serum creatinine, and C-reactive protein were
followed. RESULTS: Patients receiving TNFR:Fc had lower OKT3-ACS symptoms as measured by a scoring system. There
was a higher incidence of infection in treated patients (10/12) compared to controls (1/4) in the 3 months after transplant, but
the etiology of this difference was unclear. There were no significant differences in cytokine profiles. CONCLUSIONS:
TNFR:Fc is well tolerated by renal transplant patients receiving OKT3 induction therapy and modestly decreases the
symptoms associated with OKT3-ACS.
|
